Comparative Pharmacology
Head-to-head clinical analysis: DALBAVANCIN HYDROCHLORIDE versus VANCOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DALBAVANCIN HYDROCHLORIDE versus VANCOR.
DALBAVANCIN HYDROCHLORIDE vs VANCOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dalbavancin inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing transglycosylation and transpeptidation. It is a lipoglycopeptide antibiotic with bactericidal activity against Gram-positive bacteria.
Inhibits cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation.
1500 mg intravenously as a single dose, or 1000 mg intravenously followed by 500 mg intravenously one week later.
Vancomycin 15-20 mg/kg IV every 8-12 hours, with target trough 10-20 mcg/mL; for serious infections, consider loading dose 25-30 mg/kg IV.
None Documented
None Documented
Terminal elimination half-life of 14.4 days (range 8.5–16.0 days), permitting once-weekly dosing.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; can extend to 7-9 days in anuric patients, necessitating therapeutic drug monitoring.
Primarily renal excretion of unchanged drug (33%) and its active metabolite (12%), with additional biliary/fecal elimination (approximately 20% in feces).
Renal excretion of unchanged drug accounts for 80-90% of clearance via glomerular filtration; minor biliary excretion (<5%) and fecal elimination (<5%).
Category A/B
Category C
Glycopeptide Antibiotic
Glycopeptide Antibiotic